Quick Answer
ALX ONCOLOGY HOLDINGS INC reported Research And Development Expense of $77.00 million for the year ending 2025.
- ALX ONCOLOGY HOLDINGS INC showed a decrease of -33.8% in Research And Development Expense from 2024 to 2025.
- This data is from ALX ONCOLOGY HOLDINGS INC's annual report (Form 10-K), filed with the SEC on March 9, 2026.
- XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2019: $3.63 million | Q3 2019: $2.21 million | Q1 2020: $3.83 million | Q2 2020: $7.66 million | Q3 2020: $5.33 million | Q1 2021: $9.85 million | Q2 2021: $11.21 million | Q3 2021: $18.21 million | Q1 2022: $17.07 million | Q2 2022: $26.75 million | Q3 2022: $29.38 million | Q1 2023: $24.76 million | Q2 2023: $29.48 million | Q3 2023: $45.77 million | Q1 2024: $31.72 million | Q2 2024: $34.65 million | Q3 2024: $26.47 million | Q1 2025: $23.89 million | Q2 2025: $18.02 million | Q3 2025: $17.44 million.
- Over the full 8 years of available data (2018 to 2025), ALX ONCOLOGY HOLDINGS INC's Research And Development Expense has grown by 583.2%.
- Historical annual values: Fiscal year 2025: $77.00 million | Fiscal year 2024: $116.37 million | Fiscal year 2023: $141.80 million | Fiscal year 2022: $98.40 million | Fiscal year 2021: $60.17 million | Fiscal year 2020: $28.96 million | Fiscal year 2019: $16.31 million | Fiscal year 2018: $11.27 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: